Complications following permanent prostate brachytherapy.

OBJECTIVES The acute and chronic complications of permanent prostate brachytherapy are discussed. MATERIALS AND METHODS Review of literature for the complications associated with iodine-125 (125I) and palladium-103 (103Pd) prostate brachytherapy. Acute complications included urinary retention, changes in the International Prostate Symptom Score (IPSS) and need for TURP. Chronic morbidity included permanent urinary symptoms, incontinence, radiation proctitis and erectile dysfunction. RESULTS Urinary retention occurred in 1.5-22% of the patients postimplant. Acute urinary symptoms increased by over 100% 1 month after the procedure. By 12 months, the symptoms were either back to baseline or slightly elevated in over 90% of the patients. Significant obstructive symptoms or persistent urinary retention necessitating TURP occurred in 0-8.7%. Urinary incontinence was found in 0-19% treated by implant without associated TURP, in 0-85% for those who had a TURP prior to the implant and in 0-17% for those who had the TURP subsequent to the implant. Potency rates ranged from 34% to 86% 1-6 years postimplant. Radiation proctitis was found in 0.5-21.4%, with significant injury (fistula) occurring in 1-2.4%. CONCLUSIONS The data from this report suggests that permanent prostate brachytherapy can be accomplished with minimal short- and long-term morbidity. Attention to detail as well as an appreciation to the causative factors for the morbidity will help reduce treatment-related side effects.

[1]  R. Stock,et al.  Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. , 2001, International journal of radiation oncology, biology, physics.

[2]  G. Lederman,et al.  High dose combination radiotherapy for the treatment of localized prostate cancer. , 1998, The Journal of urology.

[3]  H. Ragde,et al.  Brachytherapy for clinically localized prostate cancer. , 2000, Seminars in surgical oncology.

[4]  S. Kalnicki,et al.  Urinary morbidity with a modified peripheral loading technique of transperineal (125)i prostate implantation. , 2000, International journal of radiation oncology, biology, physics.

[5]  Michael J. Zelefsky,et al.  Comparison of the 5-Year Outcome and Morbidity of Three-Dimensional Conformal Radiotherapy Versus Transperineal Permanent Iodine-125 Implantation for Early-Stage Prostatic Cancer , 1999 .

[6]  T W Griffin,et al.  Reduction of radioactive seed embolization to the lung following prostate brachytherapy. , 1998, International journal of radiation oncology, biology, physics.

[7]  K. Wallner,et al.  Clinical course of rectal bleeding following I-125 prostate brachytherapy. , 1998, International journal of radiation oncology, biology, physics.

[8]  J Roy,et al.  Short-term morbidity from CT-planned transperineal I-125 prostate implants. , 1993, International journal of radiation oncology, biology, physics.

[9]  T. D. de Reijke,et al.  Analysis of biopsy findings and implant quality following ultrasonically-guided 125I implantation for localised prostatic carcinoma. , 1993, British journal of urology.

[10]  T. Mate,et al.  High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. , 1998, International journal of radiation oncology, biology, physics.

[11]  K. Wallner,et al.  Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. , 1997, International journal of radiation oncology, biology, physics.

[12]  J. Cohen,et al.  Complications after prostate brachytherapy in the Medicare population. , 2000, Urology.

[13]  J Roy,et al.  Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Stock,et al.  A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. , 1995, International journal of radiation oncology, biology, physics.

[15]  K. Wallner,et al.  Comparison of outcome and morbidity of 3-dimensional conformal radiotherapy versus transperineal permanent I-125 implantation for early stage prostatic cancer , 1998 .

[16]  P. Grimm,et al.  American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. , 1999, International journal of radiation oncology, biology, physics.

[17]  J. Blasko,et al.  Brachytherapy for prostate cancer , 1995, CA: a cancer journal for clinicians.

[18]  P. Unger,et al.  Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate. , 1995, The Journal of urology.

[19]  S. Nag Principles and practice of brachytherapy , 1997 .

[20]  J. W. Stallings,et al.  Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity. , 1999, International journal of radiation oncology, biology, physics.

[21]  J Roy,et al.  Treatment-related symptoms during the first year following transperineal 125I prostate implantation. , 1994, International journal of radiation oncology, biology, physics.

[22]  H. Ragde,et al.  Ten‐year disease free survival after transperineal sonography‐guided iodine‐125 brachytherapy with or without 45‐gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinoma , 1999, Cancer.

[23]  R. Stock,et al.  Prostate brachytherapy: Improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and three-dimensional dosimetry , 1995 .

[24]  L. Potters,et al.  Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[25]  R. Stock,et al.  Prostate brachytherapy: treatment strategies. , 1999, The Journal of urology.

[26]  K. Wallner,et al.  103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. , 1996, International journal of radiation oncology, biology, physics.

[27]  PasteauO.,et al.  The Radium Treatment of Cancer of the Prostate , 1914 .

[28]  J. Blasko,et al.  American brachytherapy society survey of current clinical practice for permanent brachytherapy of prostate cancer , 1997 .

[29]  L. Potters,et al.  Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. , 1999, International journal of radiation oncology, biology, physics.

[30]  Stone Nn,et al.  Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. , 2000 .

[31]  H. Holm,et al.  Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. , 1983, The Journal of urology.

[32]  G. Grabenbauer,et al.  Early results of pulsed-dose-rate interstitial brachytherapy for head and neck malignancies after limited surgery. , 2000, International journal of radiation oncology, biology, physics.

[33]  H. Trachtman,et al.  The role of nitric oxide in obstructive nephropathy. , 2000, The Journal of urology.

[34]  F. Critz,et al.  Prostate specific antigen‐monitored combination radiotherapy for patients with prostate cancer. I‐125 implant followed by external‐beam radiation , 1995, Cancer.

[35]  J. Blasko,et al.  Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. , 1991, Scandinavian journal of urology and nephrology. Supplementum.

[36]  J. Blasko,et al.  Interstitial iodine‐125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma , 1997, Cancer.

[37]  S Nag,et al.  Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration. , 1995, Urology.

[38]  D. Beyer,et al.  Biochemical disease-free survival following 125I prostate implantation. , 1997, International journal of radiation oncology, biology, physics.

[39]  R. Stock,et al.  Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. , 1998, The Journal of urology.

[40]  J M Collins,et al.  Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. , 1998, International journal of radiation oncology, biology, physics.

[41]  J. Payne,et al.  Original Articles: Prostate Cancer , 1995 .

[42]  W. Lee,et al.  A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[43]  J. Blasko,et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.

[44]  W. Butler,et al.  Temporal resolution of urinary morbidity following prostate brachytherapy. , 2000, International journal of radiation oncology, biology, physics.

[45]  J. Roy,et al.  Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. , 1995, International journal of radiation oncology, biology, physics.